129.00 0.00 (0.00%)
After hours: 4:31PM EDT
|Bid||128.88 x 1000|
|Ask||134.00 x 900|
|Day's Range||128.52 - 131.75|
|52 Week Range||113.52 - 173.10|
|Beta (3Y Monthly)||0.99|
|PE Ratio (TTM)||11.70|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The company Jazz bought is developing a new treatment for a a nervous system disorder that causes rhythmic shaking.
Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down ...
Jazz (JAZZ) delivered earnings and revenue surprises of 13.45% and 5.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.
How far off is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) from its intrinsic value? Using the most recent financial data...
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jazz is paying $3.5 million up front, and another $203 million in contingent payments tied to hitting product development milestones, for an England company's cancer therapy program.
Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 9) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Athenex ...
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at...
The U.S. economy has stepped into the 11th year of the expansion, exhibiting the longest expansion in history. These winning ETFs and stocks will rally further.
Last August, while showing off his company’s expanded Philadelphia office space, Jazz Pharmaceuticals President and COO Dan Swisher said he wouldn’t be surprised to see the company’s Center City headcount top 200 by 2020. Jazz has already surpassed that mark, and then some. “We have 220 people in Philadelphia and another 20 open positions,” said Bruce Cozadd, the company’s co-founder, chairman and CEO.
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]